Rapport Therapeutics, INC 10-Q quarterly reports

Rapport Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in R&D and a significant collaboration agreement.

Rapport Therapeutics announces Q1 2026 results, highlighting $20 million collaboration revenue and progress in clinical trials for RAP-219.

Rapport Therapeutics, a clinical-stage biotechnology company, announced positive topline results from its Phase 2a trial of RAP-219 for drug-resistant focal onset seizures, alongside a significant capital raise and continued operating losses.

Rapport Therapeutics reports increased Q2 losses and R&D expenses, with a key pain trial on FDA clinical hold, while advancing its lead epilepsy and bipolar programs.

Rapport Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and research and development programs.

Rapport Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and a recent FDA clinical hold on a trial for diabetic peripheral neuropathic pain.

Rapport Therapeutics, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results, highlighting increased operating expenses due to ongoing clinical trials and research activities, alongside a successful IPO that significantly boosted its cash reserves.